Your immune system is attacking the glue between your skin cells
That is not a metaphor. Your skin is held together by specific proteins, and in these diseases your own antibodies bind those proteins and take them out of service. Everything else — the blisters, the erosions, the itch, the pain, the danger — follows mechanically from that single fact.
The proteins, and what binds them
- Desmosomes are the rivets between adjacent skin cells. Two of their components — desmoglein 1 and desmoglein 3 — are the targets in pemphigus. When antibodies bind them, cells detach from one another within the epidermis (acantholysis), and the skin splits at that level: fragile, flaccid blisters and raw erosions.
- Hemidesmosomes are the anchors fastening the epidermis down onto the dermis. Their components BP180 (collagen XVII) and BP230 are the targets in pemphigoid. Antibodies bind, complement is activated, eosinophils and mast cells arrive and release proteases, and the epidermis lifts off the dermis as a sheet: tense, persistent blisters.
That structural difference — inside the epidermis versus underneath it — explains everything a patient notices about the two diseases, from how fragile the blister is to whether the mouth is involved.
The most elegant fact in this disease, and the most useful
Why does pemphigus vulgaris start in the mouth, while pemphigus foliaceus never touches it?
Because the two desmogleins are distributed differently. Mucosa depends heavily on desmoglein 3. Skin carries substantial amounts of both, so each can partly compensate for the loss of the other.
- Antibodies against desmoglein 3 alone → mucosa gives way, skin holds → mucosal-dominant pemphigus vulgaris: mouth erosions, normal-looking skin.
- Antibodies against desmoglein 3 and desmoglein 1 → both give way → mucocutaneous pemphigus vulgaris.
- Antibodies against desmoglein 1 alone → skin gives way superficially, mucosa is protected by desmoglein 3 → pemphigus foliaceus: crust and scale, no mouth involvement.
This is why your antibody profile predicts where your disease will be, and why the ELISA result on your report is not an academic detail. It is the disease, written down.
Why the antibodies exist at all
The honest answer is that in your individual case, nobody can tell you. What is known:
- Loss of B-cell tolerance. Autoreactive B cells that should have been deleted or silenced survive instead, receive help from T follicular helper cells, and mature into plasma cells producing high-affinity IgG against desmoglein or BP180. In active pemphigus this is largely IgG4. In pemphigoid, complement-fixing subclasses matter, because complement is central to the damage.
- Genetic susceptibility. Particular HLA class II types are strongly associated with pemphigus: how your immune system presents these self-peptides to T cells is inherited. Susceptibility is not destiny, and this is not something you can be usefully tested for in advance.
- A trigger, sometimes. A drug, an infection, physical injury, ultraviolet exposure, radiotherapy. Often none is ever found — and not finding one usually means there was nothing to find.
- Epitope spreading. Once tolerance is broken, the response can broaden to new targets over time. It is part of why mucosal pemphigus vulgaris can later become mucocutaneous.
Why immunosuppression works, and what it leaves undone
Steroids blunt inflammation quickly, and they are a large part of why people survive this disease. Rituximab depletes CD20-positive B cells and, together with steroids, has genuinely changed the outlook in pemphigus vulgaris. It is a real advance and it belongs in this conversation with respect, not with the sneering that alternative-medicine sites reach for.
What those drugs do not do is remove the tendency to generate the response in the first place. Antibody titres often climb again. Relapse is common. And the drugs carry a real burden: infection risk, bone loss, deranged glucose, adrenal suppression, and for some people a long taper that stalls halfway down.
None of that is an argument for refusing them. It is the argument for having something working on the internal environment while they do their job. That is the whole of our claim, and we will not inflate it.
Where our work sits, and the limit of what we will say
Our protocol is formulation-based: oral compounds and topicals, couriered, taken at home. There is no procedure, no in-clinic therapy, and no clinic visit at any stage. It is supportive care alongside your dermatologist, and it is not a reason to alter a single dose of anything they have prescribed. That is their decision, and theirs alone.
The sequence is L → I → F → E → S: Lowering Inflammatory Load, then Internal Healing and Gut Repair, then Functional Detox and Immune Balancing, then External Care applied at home, then Sustaining Remission. Immune balancing sits in Phase F — and it is deliberately third, not first.
Phase F applied before Phase L has brought inflammatory load down and Phase I has stabilised internal repair mobilises internal load faster than the system can clear it — and worsens the condition. If you have ever done a detox or a cleanse and found yourself far worse a few weeks later, that is the mechanism. The approach was not wrong. The timing was.
And the limit, stated plainly: we cannot claim that our formulations lower your anti-desmoglein or anti-BP180 titre. That number belongs to your dermatologist's laboratory. It is the most objective measure in this disease; we ask for it and we record it — but recording a number is not the same as promising to move it, and we will not pretend otherwise. We do not promise a cure, and we publish no success rate. The first four to eight weeks are internal work with no expected change on the skin; months two to four are when the disease should begin to change; stable remission is assessed from month eight onward.
